HCW Biologics Inc. Share Price & Technical Analysis
HCWB · $2.89 (+12.02%)
Healthcare / Biotechnology
$2.89
+12.02%
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and i…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
625% return in May, -1% avg return in past 3 year May month.
627% return in 2026, -126% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 10% | -55% | -20% | 67% | 625% | – | – | – | – | – | – | – | 627% |
| 25 | -38% | -61% | -20% | -28% | 3% | -47% | 5% | 39% | -35% | 5% | -45% | -55% | -277% |
| 24 | -7% | 28% | 15% | -15% | -16% | -40% | -3% | -23% | 10% | -26% | 6% | -13% | -85% |
| 23 | 4% | -11% | -20% | 6% | 9% | 46% | -7% | -11% | 2% | -12% | -32% | 10% | -17% |
| 22 | -7% | -1% | 25% | -17% | -12% | 7% | 18% | 8% | -8% | -3% | -5% | -6% | -1% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Exhausted
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.07M
P/E ratio
—
52W high
$8.75
52W low
$0.25
Volume
1,93,98,024
Beta
1.14
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is HCW Biologics Inc. share price today?
- HCW Biologics Inc. (HCWB) last traded around $2.89 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HCWB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HCWB. Download the app for real-time alerts.
- How can I analyze HCW Biologics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.